Communiqués Applied DNA Sciences, Inc. BOERSE MUENCHEN

Actions

UDJ

US03815U4094

Temps réel BOERSE MUENCHEN Autres places de cotation 11:43:40 01/07/2024			Varia. 5j.	Varia. 1 janv.
0,414 ^EUR	0,00%		-0,48%	-96,49%

20/06	Applied DNA Sciences, Inc. et Alphazyme LLC concluent le projet de mise à l'échelle de la fabrication des RNAP de Linea (TM) et apportent une amélioration substantielle à l'économie de la plateforme IVT de Linea (TM)	CI
18/06	Applied DNA s'associe à GenXys pour les tests pharmacogénétiques	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Applied DNA and Alphazyme Conclude Linea RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea IVT Platform Economics	21/06	AQ
Applied DNA Partners with GenXys Health Care Systems to Deploy Clinical Decision Support System for Pharmacogenetic Testing	19/06	AQ
Applied DNA Sciences : Partners with GenXys Health Care Systems to Deploy Clinical Decision Support System for Pharmacogenetic (PGx) Testing	18/06	PU
Applied DNA Announces Notice of Allowance for U.S. Patent Covering Fundamental Aspect of its Linea IVT Platform	06/06	AQ
Applied DNA Announces Pricing of $12 Million Public Offering	29/05	AQ
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement	13/05	AQ
Applied DNA Sciences: Fiscal Q2 Earnings Snapshot	10/05	AQ
Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Program	26/04	AQ
Applied DNA to Showcase Linea DNA and Linea IVT Platforms at 24th Annual World Vaccine Congress	15/03	AQ
Applied DNA Sciences: Fiscal Q1 Earnings Snapshot	08/02	AQ
Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules	01/02	AQ
Applied DNA Announces Joint Development Agreement to Integrate Linea IVT Platform into CDMO Kudo Biotechnology's mRNA Manufacturing Workflow	15/12	AQ
Applied DNA Sciences: Fiscal Q4 Earnings Snapshot	07/12	AQ
Applied DNA to Report Fiscal 2023 Fourth Quarter and Year End Financial Results on December 7, 2023	06/12	AQ
Applied DNA Extends Application of Linea IVT Platform to saRNA	17/11	AQ
Applied DNA Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production	24/08/23	AQ
Applied DNA Sciences: Fiscal Q3 Earnings Snapshot	10/08/23	AQ
Conference Call/Webcast Scheduled for Today at 4:30 PM ET - Form 8-K	10/08/23	PU
Applied DNA Biotherapeutics Subsidiary LineaRx to Participate in Upcoming mRNA Industry Conferences	19/07/23	AQ
Applied DNA Sciences: Fiscal Q2 Earnings Snapshot	11/05/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Applied DNA Sciences, Inc. BOERSE MUENCHEN

Actions

UDJ

US03815U4094

Communiqués

Filtres